본문 바로가기
KERD
논문KCI 등재

Atypical Antipsychotics for Bipolar Disorder: Overblown or Blown Over?

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

초록

Objective:Developments in the pharmacological treatment of bipolar disorder are of much interest, as the chronicity and disability of the disorder become better understood, and as treatment goals have shifted to emphasise early control of illness course and maintenance of euthymia in addition to acute episodic remission. Atypical antipsychotics have emerged as treatment options, and this paper aims to review the evidence for their role in bipolar disorder. Methods:A MEDLINE search was conducted for publications up till October 2006. Results:The search yielded a number of randomised, controlled clinical trials of various atypical antipsychotics as monotherapy or adjunctive therapy in bipolar disorder. The majority of such trials have investigated their efficacy in acute mania, with fewer studies devoted to acute bipolar depression or maintenance treatment. There are no specific trials on mixed states, which have mainly been studied together with bipolar mania. The most robust evidence supports a class effect of atypical agents in the treatment of mania. Conclusions:There are placebo-controlled trials that support the efficacy of olanzapine and quetiapine in bipolar depression, and of olanzapine and aripiprazole as maintenance treatment. There is strong support for the role of atypical antipsychotics in bipolar disorder management despite a relatively narrow literature base, chiefly for the treatment of mania. However, these findings need to be replicated, and further investigation is warranted to clarify their spectrum of efficacy in bipolar disorder.

Abstract

Objective:Developments in the pharmacological treatment of bipolar disorder are of much interest, as the chronicity and disability of the disorder become better understood, and as treatment goals have shifted to emphasise early control of illness course and maintenance of euthymia in addition to acute episodic remission. Atypical antipsychotics have emerged as treatment options, and this paper aims to review the evidence for their role in bipolar disorder. Methods:A MEDLINE search was conducted for publications up till October 2006. Results:The search yielded a number of randomised, controlled clinical trials of various atypical antipsychotics as monotherapy or adjunctive therapy in bipolar disorder. The majority of such trials have investigated their efficacy in acute mania, with fewer studies devoted to acute bipolar depression or maintenance treatment. There are no specific trials on mixed states, which have mainly been studied together with bipolar mania. The most robust evidence supports a class effect of atypical agents in the treatment of mania. Conclusions:There are placebo-controlled trials that support the efficacy of olanzapine and quetiapine in bipolar depression, and of olanzapine and aripiprazole as maintenance treatment. There is strong support for the role of atypical antipsychotics in bipolar disorder management despite a relatively narrow literature base, chiefly for the treatment of mania. However, these findings need to be replicated, and further investigation is warranted to clarify their spectrum of efficacy in bipolar disorder.

참고문헌 (58)

  1. Kesler RC, "Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replica-tion", 62, pp.593~602 (2005)
  2. Judd LL, "A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder", 60, pp.261~269 (2003)
  3. Jud LL, "The long-term natural history of the weekly symp-tomatic status of bipolar I disorder", 59, pp.530~537 (2002)
  4. Bauer MS, "What is a mood stabilizer? An evi-dence-based response", 161, pp.3~18 (2004)
  5. Goldberg JF, "Antidepressant-induced mania: an over-view of current controversies", 5, pp.407~420 (2003)
  6. Bowden CL, "A randomized, double-blind, placebo-controled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder", 66, pp.1~121 (2005)
  7. Hirschfeld RM, "Rapid antimanic effect of risperidone mo-notherapy: a 3-week multicenter, double-blind, placebo-controled trial", 161, pp.1057~1065 (2004)
  8. Keck PE Jr, "A placebo-controled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipo-lar mania", 160, pp.1651~1658 (2003)
  9. Keck PE Jr, "Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controled, double-blind, randomized trial", 160, pp.741~748 (2003)
  10. Khana S, "Risperidone in the treatment of acute mania: double-blind, placebo-controled study", 187, pp.229~234 (2005)
  11. McIntyre RS, "Quetiapine or haloperidol as monotherapy for bipolar mania-a 12-week, double-blind, randomised, parallel-group, placebo-controled trial", 15, pp.573~585 (2005)
  12. Potkin SG, "Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controled replication trial", 25, pp.301~310 (2005)
  13. Sachs G, "Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controled study", 6, pp.213~223 (2004)
  14. Sachs G, "Ariprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controled study", pp.536~546 (2006)
  15. Sachs GS, "Combination of a mod stabilizer with risperidone or halope-ridol for treatment of acute mania: a double-blind, placebo-con-trolled comparison of eficacy and safety", 159, pp.146~1154 (2002)
  16. Smulevich AB, "Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controled trial folowed by a 9-week double-blind trial of risperidone and haloperidol", 15, pp.75~84 (2005)
  17. Tohen M, "Eficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients par-tialy nonresponsive to valproate or lithium monotherapy", 59, pp.62~69 (2002)
  18. Tohen M, "Eficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controled study. The Olanzapine HGW Study Group", 57, pp.841~849 (2000)
  19. Tohen M, "Olanzapine versus placebo in the treatment of acute mania", 156, pp.702~709 (1999), Olanzapine HGEH Study Group
  20. Yatham LN, "Mod stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial", 182, pp.141~147 (2003)
  21. Yatham LN, "Quetiapine versus placebo in combination with lithium or divalproex for the treat-ment of bipolar mania", 24, pp.599~606 (2004)
  22. Hadjakis WJ, "Aripiprazole in acute mania: results from a second placebo-controled study", 6, pp.39~40 (2004)
  23. Vieta E, "Effectiveness of ariprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-wek trial", 187, pp.235~242 (2005)
  24. Baldessarini RJ, "Olanzapine versus placebo in acute mania: treatment responses in subgroups", 23, pp.370~376 (2003)
  25. Houston JP, "Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controled trial of olanzapine com-bined with lithium or divalproex", 67, pp.1246~1252 (2006)
  26. Tohen M, "A 12-week, double-blind com-parison of olanzapine vs haloperidol in the treatment of acute mania", 60, pp.1218~1226 (2003)
  27. Shi L, "Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status", 17, pp.227~237 (2002)
  28. Shi L, "Open-label olanzapine treatment in bipolar I disorder: clinical and work functional outcomes", 22, pp.961~966 (2006)
  29. Berk M, "Olanzapine compared to lithium in mania: a double-blind randomized controlled trial", 14, pp.339~343 (1999)
  30. Tohen M, "Olanzapine versus divalproex in the treatment of acute mania", 159, pp.101~1017 (2002), Atypical Antipsychotics in Bipolar Disorder
  31. Berk M, "The Orygen first episode mania study", 9(1), pp.S44~ (2006)
  32. Vieta E, "Quetiapine monotherapy for mania associated with bipolar disorder: com-bined analysis of two international, double-blind, randomised, placebo-controled studies", 21, pp.923~934 (2005)
  33. Yatham LN, "Quetiapine in combination with mod stabiliser for the treatment of acute mania associated with bi-polar disorder", 7, pp.S330~ (2004)
  34. Hirschfeld RM, "An open-label extension trial of risperidone monotherapy in the treatment of bipolar I disorder", 21, pp.11~20 (2006)
  35. Segal J, "Risperidone compared with both li-thium and haloperidol in mania: a double-blind randomized controled trial", 21, pp.176~180 (1998)
  36. Vieta E, "Risperidone in the treatment of mania: eficacy and safety results from a large, multicentre, open study in Spain", 72, pp.15~19 (2002)
  37. Yatham LN, "Risperidone in acute and continuation treatment of mania", 18, pp.227~235 (2003)
  38. Yatham LN, "Risperidone plus lithium versus risperidone plus valproate in acute and con-tinuation treatment of mania", 19, pp.103~109 (2004)
  39. Bahk WM, "Risperidone in combination with mod stabilizers for acute mania: a multicentre, open study", 19, pp.299~303 (2004)
  40. Bowden CL, "Risperidone in com-bination with mod stabilizers: a 10-week continuation phase study in bipolar I disorder", 65, pp.707~714 (2004)
  41. Weisler R, "Adjunctive ziprasidone for bipolar mania: Short and long-term data", 7, pp.S327~ (2004)
  42. Vieta E, "A, Popova E, Comes M, et al. An open-label study of amisulpride in the treatment of mania", 66, pp.575~578 (2005)
  43. Fehr BS, "Low doses of clozapine may sta-bilize treatment-resistant bipolar patients", 255, pp.10~14 (2005)
  44. Degner D, "Clozapine in the treatment of mania", 12, pp.283~ (2000)
  45. Calabrese JR, "Clozapine for treatment-refractory mania", 153, pp.759~764 (1996)
  46. Green AI, "Clozapine in the treatment of refractory psychotic mania.", 157, pp.982~986 (2000)
  47. Suppes T, "Clinical outcome in a randomized 1-year trial of clozapine ver-sus treatment as usual for patients with treatment-resistant illness and a history of mania", 156, pp.164~1169 (1999)
  48. Ciapparelli A, "Clozapine in treatment-resistant pa-tients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month folow-up study", 64, pp.451~458 (2003)
  49. Guille C, "A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder", 61, pp.638~642 (2000)
  50. McIntyre RS, "The antidepressant effects of risperidone and olanzapine in bipolar disorder", 11, pp.218~226 (2004)
  51. Milev RV, "Open-label add-on quetiapine for bipolar depression: An eight-wek trial" (2004), New York, NY
  52. Milev R, "Ad-on quetiapine for bipolar depression: a 12-month open-label trial", 51, pp.523~530 (2006)
  53. Vieta E, "Role of risperidone in bipolar II: an open 6-month study", 67, pp.213~219 (2001)
  54. Tohen M, "Eficacy of olanzapine and olanzapine-fluoxetine combi-nation in the treatment of bipolar I depression", 61, pp.1079~1088 (2003)
  55. Corya SA, "A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treat-ment of bipolar depression", 67, pp.798~806 (2006)
  56. Calabrese JR, "A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression", 162, pp.1351~1360 (2005)
  57. Hirschfeld RM, "Quetia-pine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controled study", 67, pp.355~362 (2006)
  58. Thase ME, "Eficacy of quetiapine monotherapy in bipolar I and"

관련 논문AI추천

이 간행물의 다른 논문 (4건)